A human brain illustration connected to gut bacteria, symbolizing the link between probiotics and mental health.

Probiotic Revolution for Anxiety Relief: Unlocking the Connection Between Gut Bacteria and Mental Health

Sai Teja Thota24th February 202524th February 202501 mins

On February 17, 2025, Researchers from Duke-NUS Medical School and the National Neuroscience Institute uncovered a crucial connection between gut microbes and anxiety-related behavior. Their latest study, published in EMBO Molecular Medicine, highlights how microbial metabolites, specifically indoles, directly impact brain activity linked to anxiety. This groundbreaking discovery opens new possibilities for probiotic-based treatments aimed…

key developments pharmaceutical industry 2025

Key Developments In The Pharmaceutical Industry 2025

Shweta Agarwal18th February 202518th February 202506 mins

Last week, several significant events in the pharmaceutical industry have captured attention, signaling important shifts in investment strategies, acquisitions, and growth phases for top companies in Asia. From strategic reorientation to major acquisitions, here’s a closer look at the key developments shaping the sector. Astellas Shifts Investment Focus Astellas, known for its cutting-edge research in…

Pfizer’s Adcetris Receives FDA Approval For Treating Large B-Cell Lymphoma

Shweta Agarwal13th February 202513th February 202502 mins

Pfizer’s Adcetris (brentuximab vedotin) has secured a new FDA approval to treat patients with large B-cell lymphoma (LBCL), marking another milestone for the blood cancer drug. More than 13 years after its initial approval, Adcetris is now authorized for use in combination with lenalidomide and rituximab for certain LBCL patients who have undergone at least…

Merck KGaA In Advanced Talks To Acquire Springworks Therapeutics Amid Fda Decision On Key Drug

Shweta Agarwal13th February 202513th February 202502 mins

Merck KGaA, the German biopharma giant, is in advanced discussions to acquire SpringWorks Therapeutics, a Connecticut-based company specializing in cancer and rare disease treatments. The news, first reported by Reuters, comes as SpringWorks awaits an important FDA approval decision on its MEK inhibitor, mirdametinib, expected later this month. The potential acquisition is significant, as SpringWorks…